| Name | Tranylcypromine hemisulfate |
| Description | Tranylcypromine hemisulfate (Tranylcypromine Sulfate) is an inhibitor of monoamine oxidase (MAO) and lysine-specific demethylase 1 (LSD1) with a rapid onset of activity. |
| Animal Research | The authors evaluated whether tranylcypromine contributes to neuronal survival following stress-induced damage using primary cultured rat RGCs and in vivo N-methyl-D-aspartate (NMDA)-induced excitotoxicity.?Additionally, the molecules associated with tranylcypromine treatment were assessed by microarray and immunoblot analysis[1]. |
| In vivo | Tranylcypromine-induced transcriptional and epigenetic regulation modulated RGC survival via the promotion of p38 MAPKγ activity. Therefore, pharmacologic treatments that suppress LSD1 activity may be a novel therapeutic strategy that can be used to treat neurodegenerative diseases[1]. |
| Storage | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | H2O : 10 mg/mL (54.88 mM), Sonication is recommended.
DMSO : 3.33 mg/mL (18.27 mM), Sonication is recommended.
|
| Keywords | Tranylcypromine Hemisulfate | Tranylcypromine | MonoamineOxidase | Monoamine Oxidase | MAO | LSD1 | Inhibitor | inhibit | HistoneDemethylase | Histone Demethylase | dl-Tranylcypromine hemisulfate |
| Inhibitors Related | Procaine | Safinamide | 1,4-Naphthoquinone | 4-Chlorochalcone | Paeonol | Hydroxylamine hydrochloride | Methylene Blue trihydrate | β-Aminopropionitrile | Aminoacetone hydrochloride | Allylthiourea | Daminozide | Eicosapentaenoic Acid |
| Related Compound Libraries | Failed Clinical Trials Compound Library | Anti-Neurodegenerative Disease Compound Library | Bioactive Compound Library | Neuronal Signaling Compound Library | Drug-induced Liver Injury (DILI) Compound Library | Chromatin Modification Compound Library | Drug Repurposing Compound Library | Inhibitor Library | FDA-Approved Drug Library | Anti-Aging Compound Library | Bioactive Compounds Library Max | Covalent Inhibitor Library |
United States
